Pharmaceutical Executive
February 28, 2017
Features
37
2
Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry
February 21, 2017
Features
37
2
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
February 09, 2017
Columns
37
2
A new approach to reviving industry collaborations.
February 08, 2017
Columns
37
2
The key steps to easing rising complexity and cost factors.
February 08, 2017
From the Editor
37
2
Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.
February 06, 2017
Columns
37
2
Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.
February 01, 2017
Columns
37
2
Recent events you may have missed on the global pharma scene.
February 01, 2017
Features
37
2
With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.
February 01, 2017
Features
37
2
Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.
February 01, 2017
Special Sponsored Section
37
2
Despite serving as a regional hub for numerous leading global healthcare and life sciences companies-while simultaneously straddling the frontier of biomedical advancement and innovation-Singapore is reinventing itself yet again and spearheading a new model of Asian healthcare.
February 01, 2017
Issue PDF
37
2
Click the title above to open the Pharmaceutical Executive February 2017 issue in an interactive PDF format.
January 01, 2017
Columns
37
2
The pursuit of a harmonized European approach to assessing the value of new medicines continues to face roadblocks.